BE HEARD: Bimekizumab Shows Sustained Relief in HS Symptoms Through 3 Years

Long-term data from the BE HEARD study showed BIMZELX® (bimekizumab-bkzx) was linked with sustained reductions in draining tunnels and clinically meaningful skin pain relief in patients with moderate-to-severe hidradenitis suppurativa (HS) through three years.

According to a news release form the manufacturer (UCB), the newly reported results come from a post-hoc analysis of patients enrolled in the BE HEARD I and II trials and who continued into the BE HEARD EXT open-label extension study. UCB announced the new data had been presented the data at the 2025 Symposium on Hidradenitis Suppurativa Advances (SHSA).

According to data in the news release, patients with at least one draining tunnel at baseline (n = 425), 48.2% had none at 1 year and 62.9% at 3 years. For patients who started without draining tunnels (n = 131), 87.8% remained tunnel-free at 1 year and 90.8% at 3 years. Just 10.0% of patients reported no or mild skin pain at baseline, 51.7% did so at 1 year and 65.8% at 3 years.

“These results for bimekizumab show meaningful improvements in inflammatory lesions and skin pain to three years, and offer a valuable perspective on its sustained efficacy for patients with HS,” said Donatello Crocetta, Chief Medical Officer at UCB, in the news release. “Our research presented at SHSA underscores UCB’s commitment to providing long-term data addressing key clinical features of chronic inflammatory conditions with a high unmet need.”

Source: UCB press release. October 31, 2025.